USFDA accepts to review SPARC’s NDA for Taclantis

Sun Pharma Advanced Research Company Ltd. | Business Support | Miscellaneous | BSE: 532872 | NSE: SPARC

01 Jul 2019 Evaluate

The US Food and Drug Administration (USFDA) has accepted for review Sun Pharma Advanced Research Company’s (SPARC) New Drug Application (NDA) for Taclantis (Paclitaxel Injection Concentrate for Suspension). The NDA filing is based on successful demonstration of clinical bioequivalence of Taclantis with Abraxane and associated clinical safety data. SPARC seeks the same indications as Abraxane for Taclantis in the NDA. The USFDA confirmed that this NDA will be a standard review.

SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.

Peers

Company Name	CMP
Sagility	45.94
Prime Focus	352.35
Knowledge RealtyTrt.	113.71
Indegene	596.10
Syngene Internatl.	385.35
View more..

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.